Indeed, testosterone binding to GPRC6A has been demonstrated to activate ERK, Akt and mammalian Target of Rapamycin (mTOR) signaling pathways in a time and dose-dependent manner, resulting in an increased cell proliferation and inhibition of autophagy in prostate cancer cells [42] (Figure 1). This evidence concerns the gene MTOR and prostate carcinoma.